E
Eugene Braunwald
Researcher at Brigham and Women's Hospital
Publications - 1758
Citations - 278949
Eugene Braunwald is an academic researcher from Brigham and Women's Hospital. The author has contributed to research in topics: Myocardial infarction & TIMI. The author has an hindex of 230, co-authored 1711 publications receiving 264576 citations. Previous affiliations of Eugene Braunwald include Boston University & University of California, San Francisco.
Papers
More filters
Journal ArticleDOI
Prognostic value of plasma fibrinogen concentration in patients with unstable angina and non-Q-wave myocardial infarction (TIMI IIIB Trial)
Richard C. Becker,Christopher P. Cannon,Edwin G. Bovill,Russell P. Tracy,Bruce Thompson,Genell L. Knatterud,Amy Randall,Eugene Braunwald +7 more
TL;DR: Elevation of fibrinogen at the time of hospital admission is associated with coronary ischemic events and a poor clinical outcome in patients with unstable angina and non-Q-wave myocardial infarction participating in the Thrombolysis in Myocardial Infarction IIIB trial.
Journal ArticleDOI
Coronary-artery surgery at the crossroads.
TL;DR: The surgical treatment of coronary-artery disease began early in this century when surgical sympathectomy was reported as a successful treatment for angina pectoris.
Journal ArticleDOI
Early Angiography in Patients with Chronic Kidney Disease: A Collaborative Systematic Review
David M. Charytan,Lars Wallentin,Bo Lagerqvist,Rudolf Spacek,Robbert J. de Winter,Noam M. Stern,Eugene Braunwald,Christopher P. Cannon,Niteesh K. Choudhry +8 more
TL;DR: It is suggested that the benefits of anEarly invasive strategy are preserved in patients with CKD and that an early invasive approach reduces the risk for rehospitalization and is associated with trends of reduction in the risk of death and nonfatal re-infarction in patientswith CKD.
Journal ArticleDOI
PhosphdiesteRasE-5 Inhibition to Improve CLinical Status and EXercise Capacity in Diastolic Heart Failure (RELAX) Trial Rationale and Design
Margaret M. Redfield,Barry A. Borlaug,Greg D. Lewis,Selma F. Mohammed,Marc J. Semigran,Martin M. LeWinter,Anita Deswal,Adrian F. Hernandez,Kerry L. Lee,Eugene Braunwald +9 more
TL;DR: Although inadequate power or crossover may have contributed to negative findings in these trials, unique pathophysiology in HFpEF may mediate the differential response to neurohumoral …
Journal ArticleDOI
Clinical Outcomes in Patients With Acute Decompensated Heart Failure Randomly Assigned to Sacubitril/Valsartan or Enalapril in the PIONEER-HF Trial
David A. Morrow,Eric J. Velazquez,Adam D. DeVore,Akshay S. Desai,Carol I. Duffy,Andrew P. Ambrosy,Andrew P. Ambrosy,Yared Gurmu,Kevin McCague,Ricardo Rocha,Eugene Braunwald +10 more
TL;DR: The primary results of the randomized double-blind PIONEER-HF trial were reported demonstrating that, in comparison with enalapril, in patients hemodynamically stabilized during hospitalization for ADHF, sacubitril/ valsartan achieved a greater reduction in N-terminal pro-brain natriuretic peptide concentration, was safe and well-tolerated.